Literature DB >> 31433061

Reducing Staphylococcus aureus resistance to lysostaphin using CRISPR-dCas9.

Xia Wu1,2, Jian Zha1,2, Mattheos A G Koffas2,3, Jonathan S Dordick2,3,4,5.   

Abstract

Bacteriolytic enzymes (cell lytic enzymes) are promising alternatives to antibiotics especially in killing drug-resistant bacteria. However, some bacteria slowly become resistant to various classes of peptidoglycan hydrolases, for reasons not well studied, in the presence of growth-supporting nutrients, which are prevalent at sites of infection. Here, we show that Staphylococcus aureus, a human and animal pathogen, while susceptible to the potent staphylolytic enzyme lysostaphin (Lst) in buffered saline, is highly resistant in the rich medium tryptic soy broth (TSB). Through a series of biochemical analysis, we identified that the resistance was due to prevention of Lst-cell binding mediated by the wall teichoic acids (WTAs) present on the cell surface. Inhibition or deletion of the gene tarO responsible for the first step of WTA biosynthesis greatly reduced S. aureus resistance to Lst in TSB. To overcome the resistance, we took advantage of the gene regulation potential of CRISPR-dCas9 and demonstrated that downregulation of tarO, tarH, and/or tarG gene expression, the latter two encoding enzymes that anchor WTAs in the outer layer of cell wall peptidoglycan, sensitized S. aureus to Lst and enabled eradication of the bacterium in TSB in 24 hr. As a result, we elucidate a key mechanism of Lst resistance in metabolically active S. aureus and provide a potential approach for treating life-threatening or hard-to-treat infections caused by Gram-positive pathogens.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRISPR-dCas9; Staphylococcus aureus; lysostaphin; resistance; wall teichoic acids

Mesh:

Substances:

Year:  2019        PMID: 31433061     DOI: 10.1002/bit.27143

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  Electrostatic-Mediated Affinity Tuning of Lysostaphin Accelerates Bacterial Lysis Kinetics and Enhances In Vivo Efficacy.

Authors:  Hongliang Zhao; Susan Eszterhas; Jacob Furlon; Hao Cheng; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.

Authors:  Yongliang Fang; Jack R Kirsch; Liang Li; Seth A Brooks; Spencer Heim; Cynthia Tan; Susan Eszterhas; Hao D Cheng; Hongliang Zhao; Yan Q Xiong; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 3.  CRISPR-Based Approaches for Gene Regulation in Non-Model Bacteria.

Authors:  Stephanie N Call; Lauren B Andrews
Journal:  Front Genome Ed       Date:  2022-06-23

4.  Synthetic antimicrobial peptides as enhancers of the bacteriolytic action of staphylococcal phage endolysins.

Authors:  Ana Gouveia; Daniela Pinto; Helena Veiga; Wilson Antunes; Mariana G Pinho; Carlos São-José
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

Review 5.  Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections.

Authors:  Yuye Wu; Dheerendranath Battalapalli; Mohammed J Hakeem; Venkatarao Selamneni; Pengfei Zhang; Mohamed S Draz; Zhi Ruan
Journal:  J Nanobiotechnology       Date:  2021-12-04       Impact factor: 10.435

Review 6.  CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies.

Authors:  Manuel González de Aledo; Mónica González-Bardanca; Lucía Blasco; Olga Pacios; Inés Bleriot; Laura Fernández-García; Melisa Fernández-Quejo; María López; Germán Bou; María Tomás
Journal:  Antibiotics (Basel)       Date:  2021-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.